Atox Bio publishes data on flesh eating bacteria treatment
NSTI, or flesh eating bacteria as it is more commonly referred to, is a life-threatening bacterial infection with significant morbidity and no approved therapies. It is a fast progressing infection that represents the most severe forms of skin and soft tissue infections and results in extensive tissue destruction.
"The results with AB103 are impressive," Alan S. Cross, professor of medicine at University of Maryland in Baltimore, Center for Vaccine Development, and the paper's lead co-author, said. "Unlike the case with other agents assessed in animal models, AB103 is highly effective even when given several hours after infection."
The findings with AB103 are significant because they also suggest that AB103 has a broad therapeutic window and could be used in cases of antibiotic ineffectiveness. This new research supports the results obtained in the recently completed Phase 2a clinical trial.
"Our insight into how an excessive inflammatory response is generated via the newly identified bottleneck of the CD28 co-stimulatory receptor, now allows for more effective treatment of live bacterial infection," Raymond Kaempfer, professor of molecular biology and cancer research at the Faculty of Medicine of The Hebrew University of Jerusalem, Israel, Atox Bio's Chief Scientist and the paper's second lead co-author, said.